RESUMEN
Background:Changes in blood cell profile were common findings in malaria. In the rural community of Kano State, Nigeria, information on haematological changes in human malaria was scanty in spite of their role in the pathophysiology of malaria. This cross-sectional study was undertaken to determine blood cell profiles in malaria patients attending a rural hospital in malaria-endemic region.Methods:Blood samples (3ml each) were collected in EDTA-containers from 150 randomly selected outpatients attending Gaya General Hospital, screened for malaria using RDT kit (CareStart Malaria HRP 2, Access Bio Inc., USA) based on Histidine-rich protein 2 (PfHRP-2), and blood cell profiles determined using automated Sysmex haematologic analyser. Data on socio-demographics and medical history related to the study objectives, such as taking antimalarial regimen and/or haematinic, and direct involvement in blood transfusion, were obtained by questionnaire administration supplemented with oral interview Findings:The study revealed amalaria prevalence of 67.33%, with highest in 11-20years (80.95%) and lowest (55.00%) in 1-10years age-groups; slightly higher in females (68.25%) than in males (66.67%) without significant difference (P<0.05). For blood parameters, malaria positive patients have a significantly lower mean PCV of 32.2% as compared to 38.18% obtained for malaria negative patients (P<0.05). The mean Hb was 10.76±2.27g/dL and 12.65±2.38g/dL (P<0.05), while WBC revealed 6.91×109/L and 6.56×109/L in malaria positive and negative patients, respectively. Platelet counts recorded 179.24×109/L and 230.47×109/L (P<0.05). Socio-demographic factors such as level of education, occupation and marital status did not significantly influence malaria prevalence. Interpretation:Low PCV and Hb in malaria patients indicate mild anaemia due to malaria-related haemolysis. The occurrence of thrombocytopenia may be due to other underlying pathology as further studies with larger sample size are needed to ascertain the cause of low platelet counts in malaria patients in the study area
RESUMEN
Background: For effective malaria control at the community level, information on the treatment practices are essential. However, there is no information on malaria treatment practices in Ibusa community. Thus, this study seeks to assess the prevalence of malaria and health care seeking behaviors in Ibusa community. Study Design: A descriptive cross-sectional study. Place and Duration of Study: Ibusa, Oshimili North Local Government area in Nigeria. The study was untaken between June and November, 2006. Methods: Malaria treatment practices including sources of anti-malarial of the 600 individuals who visited the Fenlab Diagnostic and Research Laboratory Ibusa, Delta State were obtained using a previously validated structured questionnaire. Microscopy was used to establish malaria infection and species identification. Results: The prevalence rate was found to be 73.3% and all were infections of Plasmodium falciparium. The age prevalence showed an undulating pattern however, the prevalence was highest among subjects within age group 20-29 years (31.81%) and least in age group 40-49 years (8.64%). Chi-square analysis showed no significant difference (X2 =13.61, df=5, P=0.183). The prevalence by sex showed higher values in females (60.22%) than males (39.78%), but the difference was not statistically significant at (X2=0.027, df=1, P=0.870). The malaria management practices showed that 20.83% participants buy anti-malarials from shops, 17.33% visit hospitals, while 16.33% employ traditional medicine from local healers. However, some of the subjects employ a combination of approaches. 13.83% get anti-malarials from shops, hospitals and local healers, 10.50% get anti-malarials from shops and hospitals, 9.67% visit local healers and hospitals, while 0.33% do not employ any treatment practices. Conclusion: Given the high prevalence of malaria infection in Ibusa community, proper education of the people on the need to employ proper malaria treatment practice is essential.
RESUMEN
OBJECTIVE@#To investigate resistance and safety of HHPG-19K in treating non-small cell lung cancer patients.@*METHODS@#A total of 30 cases were selected and randomly divided into 5 groups: three HHPG-19K groups of different dosage (60 μg/kg/day, 100 μg/kg/day, 200 μg/kg/day), positive control group (Filgrastim, namely G-CSF5 μg/kg/day) and negative control group. Safety indexes of 5 groups were observed and compared.@*RESULTS@#All patients had adverse event (100%) in three HHPG-19K groups, and increased ALP, ALT and AST were main events. The degree was mild to moderate. There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference. But the incidence of negative control group was 13%, which was significantly lower than dosage groups and positive control group.@*CONCLUSIONS@#non-small cell lung cancer patients have satisfactory tolerance to HHPG-19K, and have no resistance. Besides, dosage at 100 μ g/kg is the most safe.